AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12519437 — intervention group
Group type: EXPERIMENTAL
Intervention: WBC-reduced RBC with middle residual WBC concentration
Number of subjects: 105
Study 12519437 — intervention group
Group type: EXPERIMENTAL
Intervention: WBC-reduced RBC with high residual WBC concentration
Number of subjects: 105
Study 12519437 — intervention group
Group type: COMPARATOR
Intervention: Comparison between middle and high residual WBC groups
Number of subjects: 105
Study 10648316 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-mL bolus dose with a 25-min lockout interval
Number of subjects: 203
Study 10648316 — intervention group
Group type: COMPARATOR
Intervention: 4-mL bolus dose with an 8-min lockout interval
Number of subjects: 203
Study 9017785 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-lipoxygenase inhibitors
Number of subjects: 0
Study 9017785 — intervention group
Group type: EXPERIMENTAL
Intervention: cysLT receptor antagonists
Number of subjects: 0
Study 9017785 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-lipoxygenase inhibitors and cysLT receptor antagonists
Number of subjects: 0
Study 8382228 — intervention group
Group type: EXPERIMENTAL
Intervention: pyrophosphate containing cleaning gel
Number of subjects: 30
Study 8382228 — intervention group
Group type: COMPARATOR
Intervention: placebo gel
Number of subjects: 30
Study 3017551 — intervention group
Group type: EXPERIMENTAL
Intervention: Carmustine (BCNU) - 80 mg/m2 iv daily X 3 every 6 weeks
Number of subjects: 278
Study 3017551 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacarbazine (DTIC) - 175 mg/m2 iv daily X 5 every 4 weeks
Number of subjects: 278
Study 3017551 — intervention group
Group type: COMPARATOR
Intervention: Procarbazine (PCB) - 100 mg/m2 orally
Number of subjects: 278
Study 29538626 — intervention group
Group type: EXPERIMENTAL
Intervention: HINTS intervention
Number of subjects: 167
Study 29538626 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 167
Study 27259568 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised programming protocol (long detection times of 30/40 or equivalent and high rate detection zones of 200 bpm)
Number of subjects: 270
Study 27259568 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised programming protocol
Number of subjects: 270
Study 27259568 — intervention group
Group type: COMPARATOR
Intervention: Physician-led group
Number of subjects: 270
Study 24885437 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 152
Study 24885437 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 152
Study 22549390 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiedu granules plus cinobufacini injection (CM group)
Number of subjects: 120
Study 22549390 — intervention group
Group type: COMPARATOR
Intervention: Transcatheter arterial chemoembolization (TACE group)
Number of subjects: 120
Study 20353469 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 days valganciclovir prophylaxis (900 mg once daily)
Number of subjects: 326
Study 20353469 — intervention group
Group type: COMPARATOR
Intervention: 100 days valganciclovir prophylaxis (900 mg once daily)
Number of subjects: 326
Study 18419349 — intervention group
Group type: EXPERIMENTAL
Intervention: High-potency live-attenuated Oka/Merck varicella-zoster virus (VZV) vaccine
Number of subjects: 1395
Study 15863796 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg i.m. of olanzapine
Number of subjects: 311
Study 15863796 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg i.m. of haloperidol
Number of subjects: 311
Study 15863796 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular placebo
Number of subjects: 311
Study 11862501 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care plus MLT (20 mg/day orally during the dark period)
Number of subjects: 1640
Study 11862501 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus MLT (20 mg/day orally during the dark period)
Number of subjects: 1640
Study 11862501 — intervention group
Group type: COMPARATOR
Intervention: Supportive care alone
Number of subjects: 1640
Study 11862501 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 1640
Study 10350950 — intervention group
Group type: EXPERIMENTAL
Intervention: Group mean centering
Number of subjects: 0
Study 10350950 — intervention group
Group type: COMPARATOR
Intervention: Standard analysis of covariance (ANCOVA)
Number of subjects: 0
Study 10350950 — intervention group
Group type: COMPARATOR
Intervention: Analyzing each site separately
Number of subjects: 0
Study 7586608 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin (2 micrograms/kg i.v.)
Number of subjects: 12
Study 7586608 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (100 micrograms/kg i.v.)
Number of subjects: 12
Study 7586608 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin + Naloxone
Number of subjects: 12
Study 7586608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1918275 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous urokinase (UK) 72,000 IU injected over 10 minutes and UK 528,000 IU by drip infusion over 12 or 24 hours (UK group, n = 76)
Number of subjects: 166
Study 1918275 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy without urokinase (control group, n = 90)
Number of subjects: 166
Study 1918275 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous urokinase (UK) (UK group, n = 43)
Number of subjects: 166
Study 1918275 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy without urokinase (control group, n = 32)
Number of subjects: 166
Study 1918275 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous urokinase (UK) (UK group, n = 66)
Number of subjects: 166
Study 1918275 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy without urokinase (control group, n = 68)
Number of subjects: 166
Study 1918275 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous urokinase (UK) (UK group, n = 10)
Number of subjects: 166
Study 1918275 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy without urokinase (control group, n = 22)
Number of subjects: 166
Study 6130665 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of ordinary therapy until planned cholecystectomy under neurolept anaesthesia (n = 13)
Number of subjects: 26
Study 6130665 — intervention group
Group type: COMPARATOR
Intervention: 4-day gradual withdrawal of beta-receptor blockers (n = 13)
Number of subjects: 26
Study 30300265 — intervention group
Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy (PPV)
Number of subjects: 110
Study 30300265 — intervention group
Group type: EXPERIMENTAL
Intervention: Releasable scleral buckling (RSB)
Number of subjects: 110
Study 31163519 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone combined with peripheral vestibular rehabilitation therapy
Number of subjects: 50
Study 31163519 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone only (Control)
Number of subjects: 50
Study 28893134 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab (100 mg)
Number of subjects: 462
Study 28893134 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab (300 mg)
Number of subjects: 462
Study 28893134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 462
Study 28893134 — intervention group
Group type: COMPARATOR
Intervention: Mepolizumab (100 mg) vs Placebo
Number of subjects: 462
Study 28893134 — intervention group
Group type: COMPARATOR
Intervention: Mepolizumab (300 mg) vs Placebo
Number of subjects: 462
Study 28893134 — intervention group
Group type: COMPARATOR
Intervention: Overall modified intention-to-treat population
Number of subjects: 462
Study 27808277 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney surface cooling (ice bag technique, IBT group)
Number of subjects: 23
Study 27808277 — intervention group
Group type: COMPARATOR
Intervention: Standard technique (control group)
Number of subjects: 23
Study 27808277 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney surface cooling (IBT group)
Number of subjects: 23
Study 23417600 — intervention group
Group type: EXPERIMENTAL
Intervention: cAAI
Number of subjects: 45
Study 23417600 — intervention group
Group type: EXPERIMENTAL
Intervention: AAI
Number of subjects: 45
Study 23417600 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS
Number of subjects: 45
Study 21483000 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil
Number of subjects: 529
Study 21483000 — intervention group
Group type: COMPARATOR
Intervention: Fludarabine with or without cyclophosphamide
Number of subjects: 529
Study 21483000 — intervention group
Group type: EXPERIMENTAL
Intervention: TP53 mutations
Number of subjects: 529
Study 19299681 — intervention group
Group type: EXPERIMENTAL
Intervention: IMCI training plus study supports (job aids, nonfinancial incentives, and supervision)
Number of subjects: 1244
Study 19299681 — intervention group
Group type: COMPARATOR
Intervention: IMCI training plus usual supports
Number of subjects: 1244
Study 19299681 — intervention group
Group type: COMPARATOR
Intervention: Untrained workers
Number of subjects: 1244
Study 17561044 — intervention group
Group type: EXPERIMENTAL
Intervention: Cepacol
Number of subjects: 17
Study 17561044 — intervention group
Group type: EXPERIMENTAL
Intervention: Periogard
Number of subjects: 17
Study 17561044 — intervention group
Group type: COMPARATOR
Intervention: Sterile tap water
Number of subjects: 17
Study 15581523 — intervention group
Group type: EXPERIMENTAL
Intervention: Safer Choices intervention
Number of subjects: 3869
Study 15581523 — intervention group
Group type: COMPARATOR
Intervention: Standard knowledge-based HIV-education program
Number of subjects: 3869
Study 11234601 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% ropivacaine
Number of subjects: 45
Study 11234601 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 45
Study 11234601 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 45
Study 9649009 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy (various regimens including intravenous mitomycin plus 5‐fluorouracil, oral 5‐FU, intravenous methotrexate plus 5‐FU, intravenous cisplatin plus 5‐FU, hepatic arterial infusion of 5‐FU plus oral 5‐FU)
Number of subjects: 100
Study 9649009 — intervention group
Group type: COMPARATOR
Intervention: Control group (no postoperative chemotherapy)
Number of subjects: 100
Study 9649009 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy
Number of subjects: 100
Study 7517720 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) as a single agent before conventional remission induction therapy
Number of subjects: 0
Study 7517720 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified, but implied as acute nonlymphoblastic leukemia (ANLL) blasts)
Number of subjects: 0
Study 7517720 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 0
Study 2915237 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable ports
Number of subjects: 264
Study 2915237 — intervention group
Group type: COMPARATOR
Intervention: Broviac catheters
Number of subjects: 264
Study 2915237 — intervention group
Group type: COMPARATOR
Intervention: Hickman catheters
Number of subjects: 264
Study 31937026 — intervention group
Group type: EXPERIMENTAL
Intervention: Holistic nursing (experimental group)
Number of subjects: 120
Study 31937026 — intervention group
Group type: COMPARATOR
Intervention: Conventional nursing (control group)
Number of subjects: 120
Study 27640142 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezoelectric device
Number of subjects: 90
Study 27640142 — intervention group
Group type: COMPARATOR
Intervention: Conventional instruments
Number of subjects: 90
Study 25392337 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized rehabilitation group (PRG)
Number of subjects: 32
Study 25392337 — intervention group
Group type: COMPARATOR
Intervention: Traditional rehabilitation group (TRG)
Number of subjects: 32
Study 25392337 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PRG and TRG)
Number of subjects: 32
Study 23517517 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily handwashing with soap, daily brushing with fluoride toothpaste, biannual deworming with 400 mg albendazole (Essential Health Care Program [EHCP])
Number of subjects: 412
Study 23517517 — intervention group
Group type: COMPARATOR
Intervention: Control group (external concurrent control)
Number of subjects: 412
Study 23517517 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (EHCP)
Number of subjects: 412
Study 21410861 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 42
Study 21410861 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 42
Study 18599554 — intervention group
Group type: EXPERIMENTAL
Intervention: rs1151640 polymorphism in the OR13G1 gene
Number of subjects: 2145
Study 18599554 — intervention group
Group type: EXPERIMENTAL
Intervention: rs11881940 polymorphism in the HNRPUL1 gene
Number of subjects: 2145
Study 18599554 — intervention group
Group type: EXPERIMENTAL
Intervention: rs3746731 polymorphism in the CD93 gene
Number of subjects: 2145
Study 18599554 — intervention group
Group type: EXPERIMENTAL
Intervention: rs10757274 polymorphism near the CDKN2A and CDKN2B genes
Number of subjects: 2145
Study 16783467 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion rate of IGIV-C, 10% at 0.14 mL/kg/min
Number of subjects: 97
Study 16783467 — intervention group
Group type: COMPARATOR
Intervention: Infusion rate of IGIV-C, 10% at 0.08 mL/kg/min (standard rate)
Number of subjects: 97
Study 16783467 — intervention group
Group type: EXPERIMENTAL
Intervention: Both rates of infusion (0.08 mL/kg/min and 0.14 mL/kg/min)
Number of subjects: 97
Study 16783467 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased rate of infusion of IGIV-C, 10%
Number of subjects: 97
Study 16783467 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased rate of infusion of IGIV-C, 10% at 0.14 mL/kg/min
Number of subjects: 97
Study 14564363 — intervention group
Group type: EXPERIMENTAL
Intervention: Peach allergy confirmed by double-blind, placebo-controlled food challenges
Number of subjects: 100
Study 14564363 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick tests with fresh peach and purified peach LTP (Pru p 3)
Number of subjects: 100
Study 14564363 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific IgE determinations to peach, rBet v 1, and rBet v 2
Number of subjects: 100
Study 14564363 — intervention group
Group type: COMPARATOR
Intervention: Comparison of sensitization rates
Number of subjects: 100
Study 14564363 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE responses to rBet v 2
Number of subjects: 100
Study 11712301 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-term newborns
Number of subjects: 114
Study 11712301 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborns with congenital heart defects
Number of subjects: 114
Study 11712301 — intervention group
Group type: COMPARATOR
Intervention: Full-term newborns
Number of subjects: 114
Study 8705098 — intervention group
Group type: EXPERIMENTAL
Intervention: Early postoperative breast feeding
Number of subjects: 40
Study 8705098 — intervention group
Group type: COMPARATOR
Intervention: Spoon feeding
Number of subjects: 40
Study 1642915 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (TNG) 200 micrograms
Number of subjects: 32
Study 1642915 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 1,600 micrograms
Number of subjects: 32
Study 1642915 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (TNG) and Isosorbide dinitrate (ISDN)
Number of subjects: 32
Study 7021412 — intervention group
Group type: EXPERIMENTAL
Intervention: Kallikrein treatment
Number of subjects: 20
Study 30190369 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib + modified FOLFOX (sorafenib 400 mg twice a day for 2 weeks, followed by mFOLFOX: 5-FU 1200 mg/m2/day for 46 hours, leucovorin 200 mg/m2, oxaliplatin 85 mg/m2 biweekly)
Number of subjects: 40
Study 30190369 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib alone
Number of subjects: 40
Study 27908967 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F‐AV‐1451
Number of subjects: 16
Study 27908967 — intervention group
Group type: EXPERIMENTAL
Intervention: SUVR calculated over an imaging window of 80‐100 min
Number of subjects: 16
Study 27908967 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical SUVR curves
Number of subjects: 16
Study 27908967 — intervention group
Group type: EXPERIMENTAL
Intervention: Distribution volume (130 min)
Number of subjects: 16
Study 25473939 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD5423 (75 or 300 μg) once daily for 7 days
Number of subjects: 20
Study 25473939 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD5423 (300 μg)
Number of subjects: 20
Study 25473939 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD5423 (75 μg)
Number of subjects: 20
Study 25473939 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (200 μg twice daily)
Number of subjects: 20
Study 24221838 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital treatments for AMI
Number of subjects: 18000
Study 21402409 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms during pregnancy
Number of subjects: 217
Study 21402409 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy intention
Number of subjects: 217
Study 19772502 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide retard therapy for 8 weeks
Number of subjects: 0
Study 17519152 — intervention group
Group type: EXPERIMENTAL
Intervention: CARRA/LNG containing 0.75 mg LNG per 4 mL of gel
Number of subjects: 12
Study 17519152 — intervention group
Group type: EXPERIMENTAL
Intervention: CARRA/LNG containing 1.5 mg LNG per 4 mL of gel
Number of subjects: 12
Study 17519152 — intervention group
Group type: COMPARATOR
Intervention: Both doses of CARRA/LNG
Number of subjects: 12
Study 15219640 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol pre-treatment
Number of subjects: 16
Study 15219640 — intervention group
Group type: COMPARATOR
Intervention: Placebo pre-treatment
Number of subjects: 16
Study 11579345 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 135
Study 11579345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 9642484 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (CCBs) with pravastatin (lipid-lowering therapy)
Number of subjects: 0
Study 9642484 — intervention group
Group type: COMPARATOR
Intervention: Calcium channel blockers (CCBs)
Number of subjects: 0
Study 9642484 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (lipid-lowering therapy)
Number of subjects: 0
Study 8124699 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive fluoride varnish program
Number of subjects: 100
Study 8124699 — intervention group
Group type: COMPARATOR
Intervention: Standard biannual fluoride varnish program
Number of subjects: 100
Study 2528022 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined immunosuppressive therapy (prednisone, cyclophosphamide, azathioprine)
Number of subjects: 31
Study 2528022 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane plasmapheresis (in addition to immunosuppressive therapy)
Number of subjects: 31
Study 2528022 — intervention group
Group type: COMPARATOR
Intervention: No specific therapy
Number of subjects: 31
Study 791477 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and vincristine (CV)
Number of subjects: 0
Study 791477 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, vincristine, and procarbazine (CVP)
Number of subjects: 0
Study 791477 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with disease confined to skin, subcutaneous tissue nodes, lung, or pleura
Number of subjects: 0
Study 791477 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders
Number of subjects: 0
Study 30037818 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipatasertib 400 mg with abiraterone 1,000 mg
Number of subjects: 0
Study 30037818 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipatasertib 200 mg with abiraterone 1,000 mg
Number of subjects: 0
Study 30037818 — intervention group
Group type: COMPARATOR
Intervention: Placebo with abiraterone 1,000 mg
Number of subjects: 0
Study 28182502 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (140ml, 12.5mmol nitrate)
Number of subjects: 10
Study 25627092 — intervention group
Group type: EXPERIMENTAL
Intervention: hybrid‐CIMT (n=25)
Number of subjects: 53
Study 25627092 — intervention group
Group type: COMPARATOR
Intervention: standard care (n=19)
Number of subjects: 53
Study 24094463 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of AT-III 100 U/kg IV for 20 minutes
Number of subjects: 20
Study 24094463 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of AT-III 100 U/kg IV for 20 minutes
Number of subjects: 20
Study 24094463 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 20
Study 20924596 — intervention group
Group type: EXPERIMENTAL
Intervention: Soccer training (SOC)
Number of subjects: 35
Study 20924596 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval running (INT)
Number of subjects: 35
Study 20924596 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous running (RUN)
Number of subjects: 35
Study 20924596 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 35
Study 19453044 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Sugiura procedure
Number of subjects: 51
Study 19453044 — intervention group
Group type: COMPARATOR
Intervention: Simplified Sugiura procedure
Number of subjects: 51
Study 19453044 — intervention group
Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 51
Study 18086050 — intervention group
Group type: EXPERIMENTAL
Intervention: smooth-gel hyaluronic acid dermal fillers
Number of subjects: 439
Study 18086050 — intervention group
Group type: COMPARATOR
Intervention: cross-linked bovine collagen
Number of subjects: 439
Study 15537681 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin (1000 mg)
Number of subjects: 167
Study 15537681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study 11887498 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency oscillation
Number of subjects: 0